Dominari Holdings (Dominari Holdings) Short Interest

View and export this data going back to 1984. Start your Free Trial

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison

For the Biotechnology subindustry, Dominari Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dominari Holdings Short Interest Distribution

For the Biotechnology industry and Healthcare sector, Dominari Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Dominari Holdings's Short Interest falls into.

Dominari Holdings (Dominari Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dominari Holdings Inc (NAS:DOMH) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

BP2A:Germany

Address

One Rockefeller Plaza, 11th Floor, New York, NY, USA, 10020

Website

https://www.dominariholdings.com

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Executives

Kyle Michael Wool	director	650 5TH AVE, 35TH FLOOR, NEW YORK NY 10019
Christopher Franklin Devall	officer: Chief Operating Officer	DOMINARI HOLDINGS INC., ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Anthony Hayes	director, officer: Chief Executive Officer	1796 SHADY LANE, COLUMBIA SC 29206
George Way	officer: Chief Financial Officer	C/O DOMINARI HOLDINGS INC., 725 5TH AVENUE 23RD FLOOR, NEW YORK NY 10022
Soo Yu	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Tim S Ledwick	director	10200 INNOVATION DRIVE, SUITE 300, MILWAUKEE WI 53226
Gregory James Blattner	director	ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY 10020
Paul Lemire	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Robert Frederick Dudley	director	ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY 10020
Zanden Robert J Vander	director	913 HIGH KNOLL WAY, TRAVELERS REST SC 29690
Eric Weisblum	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Howard E Goldberg	director	781 THIRD AVENUE, KING OF PRUSSIA PA 194061409
Frank Reiner	officer: Interim CFO	6430 ROCKLEDGE DRIVE, SUITE 503, BETHESDA MD 20817
Jeffrey Ballabon	director	6430 ROCKLEDGE DRIVE, BETHESDA NY 20817
Richard Cohen	officer: Chief Financial Officer	C/O DUNE ENERGY, INC., TWO SHELL PLAZA, 777 WALKER STREET, SUITE 2300, HOUSTON TX 77002